Moreover, anti-progestin activity is also observed by the more PR selective next-generation SPRM, telapristone acetate (TPA) which minimizes off target effects while inhibiting in vivo tumor growth and in vitro cell proliferation [113,114,115,116]. The gene discussed is PGR; the disease is neoplasm.